Cagrilintide + Semaglutide — 2.5 mg + 2.5 mg & 5 mg + 5 mg

Cagrilintide + Semaglutide combines two research peptides that approach metabolic signaling through different systems. Cagrilintide is studied through the amylin pathway, while semaglutide is studied through GLP-1 receptor signaling.

Researchers examine the combination to better understand how these two signaling systems may interact across appetite, satiety, glucose regulation, energy intake, gastric biology, and body-weight-related research.

Technical Identity: This combination is commonly characterized by two components: cagrilintide, a long-acting amylin analogue, and semaglutide, a modified GLP-1 analogue and GLP-1 receptor agonist.

Azyven Research Cagrilintide + Semaglutide is supplied exclusively for laboratory research and analytical use.

What is Cagrilintide + Semaglutide?

This formulation combines a long-acting amylin analogue with a GLP-1 receptor agonist. Each component has its own research history and receptor biology, allowing researchers to examine two distinct metabolic signaling systems within one formulation.

Why is Cagrilintide + Semaglutide studied?

The combination has attracted research interest because amylin and GLP-1 participate in overlapping but distinct aspects of metabolic regulation.

Researchers investigate whether engaging both systems creates biological responses that differ from studying either pathway alone.

What research areas are associated with Cagrilintide + Semaglutide?

Amylin-Signaling Research
Cagrilintide provides the formulation's amylin-related component, associated with satiety, food-intake, and gastric signaling.

GLP-1-Receptor Research
Semaglutide provides sustained GLP-1 receptor activity associated with glucose-dependent metabolic signaling, appetite, and satiety.

Appetite & Energy-Intake Research
Studies have examined the combination in relation to food intake, satiety, and body-weight biology.

Glucose & Metabolic Research
The two pathways provide a model for investigating glucose regulation and broader metabolic signaling.

Multi-Pathway Research
The formulation is particularly relevant to questions about how complementary hormonal pathways interact.

What have studies found?

Published research has examined cagrilintide and semaglutide both individually and in combination.

Complementary receptor biology
The two compounds engage distinct signaling systems, giving researchers a model for simultaneous amylin-related and GLP-1-receptor activity.

Body-weight-related outcomes
Clinical studies of the combination have reported changes in body-weight-related measures.

Metabolic research
Research has also evaluated glucose-related and other metabolic outcomes associated with combined signaling.

Evidence context
Findings for cagrilintide alone, semaglutide alone, and the combined formulation should be treated as separate evidence sets rather than assumed to be interchangeable.

How does Cagrilintide + Semaglutide relate to other Azyven products?

Azyven also offers Cagrilintide and Semaglutide as standalone research products, allowing each signaling pathway to be examined independently.

Researchers may also compare this dual-pathway formulation with Tirzepatide or GLP-3, which investigate different multi-receptor approaches to metabolic signaling.

Researchers can ask Aria Jr. to compare these receptor systems, components, and associated research areas.

What am I purchasing?

Azyven Research Cagrilintide + Semaglutide is supplied as a lyophilized combination research material in the strength selected above.

Available Strengths: 2.5 mg + 2.5 mg and 5 mg + 5 mg
Form: Lyophilized powder
Product Type: Research Peptide Blend
Intended Use: Laboratory research only

Research Use Only: Azyven Research products are intended for laboratory research purposes only. They are not intended for human or veterinary use, consumption, administration, or clinical application.